A secondary analysis of the RESCUE trial investigated whether IL-6 inhibition with ziltivekimab, a novel therapeutic monoclonal antibody against IL-6, changes the neutrophil-lymphocyte ratio (NLR) in patients with CKD and elevated hsCRP.
4 things to know about CKD and SGLT2i To what extent does the evidence of RCTs on use of SGLT2i in patients with CKD translate to clinical practice? Meg Jardine gives an overview of studies and provides tools to increase uptake of SGLT2I in this field.
Patients with HF may experience a transient decline in eGFR of up to 15-20% after initiation of sacubitril/valsartan. But how does this affect treatment effects? This post hoc analysis of the PARADIGM-HF and PARAGON-HF study offers more insight.
In the prespecified FIDELITY analysis, the authors investigated the causes of mortality in patients with CKD and T2DM treated with the nonsteroidal MRA finerenone or placebo.
In this prespecified analysis of the DELIVER trial, the authors evaluated whether baseline kidney function modified the effect of the SGLT2i dapagliflozin on CV improvement in patients with HFmrEF or HFpEF, and determined the effect of dapagliflozin treatment on kidney outcomes.
ACC.23 "Early treatment-related eGFR decline should not stall uptitration or impede continuation of ARNI", says Safia Chatur. She lists the findings of an analysis of PARADIGM-HF and PARAGON-HF in patients with HF.
The European Commission approved a label update to extend the indication of finerenone to early stages of CKD in patients with T2DM.
In a post-hoc analysis of the pooled FIDELITY dataset, finerenone’s cardiorenal benefits over placebo in T2DM patients with CKD were not modified by these 4 factors. Notably, HbA1c variability was associated with greater risk of cardiorenal outcomes.
4 things to know about CKD and SGLT2i Prof. David Wheeler illustrates which patients with CKD should be treated with SGLT2 inhibitors using three case studies.
4 things to know about CKD and SGLT2i Prof. Heerspink explains in this video that SGLT2i slow the progression of CKD, and reduce the risk of kidney failure and acute kidney injury.
The SGLT2 inhibitor empagliflozin reduces the risk of cardiovascular death or first hospitalization for HF in patients with HF and an LVEF >40%, compared with placebo. It is unclear whether this effect is modified by SBP.
A Taiwanese observational study evaluated CV and renal outcomes in statin-treated patients with stage 3 CKD across different LDL‐c levels.